DK1248618T3 - Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl - Google Patents

Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Info

Publication number
DK1248618T3
DK1248618T3 DK00980817T DK00980817T DK1248618T3 DK 1248618 T3 DK1248618 T3 DK 1248618T3 DK 00980817 T DK00980817 T DK 00980817T DK 00980817 T DK00980817 T DK 00980817T DK 1248618 T3 DK1248618 T3 DK 1248618T3
Authority
DK
Denmark
Prior art keywords
polymorphic
amorphous
methanesulfonylphenyl
bipyridinyl
chloro
Prior art date
Application number
DK00980817T
Other languages
English (en)
Inventor
James A Mccauley
Richard D Tillyer
Sophie Dorothee Clas
Paul O'shea
Chad Dalton
Louis S Crocker
Ian Davies
Original Assignee
Merck Frosst Canada Inc
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc, Merck & Co Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of DK1248618T3 publication Critical patent/DK1248618T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK00980817T 1999-11-29 2000-11-27 Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl DK1248618T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29

Publications (1)

Publication Number Publication Date
DK1248618T3 true DK1248618T3 (da) 2006-07-10

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00980817T DK1248618T3 (da) 1999-11-29 2000-11-27 Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (da)
EP (1) EP1248618B1 (da)
JP (1) JP4425514B2 (da)
AT (1) ATE320809T1 (da)
AU (1) AU776544B2 (da)
CA (1) CA2391650C (da)
DE (1) DE60026877T2 (da)
DK (1) DK1248618T3 (da)
ES (1) ES2259295T3 (da)
PT (1) PT1248618E (da)
WO (1) WO2001037833A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
PL2401253T3 (pl) 2009-02-27 2016-05-31 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
EA023286B1 (ru) * 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Способ получения полиморфной формы i эторикоксиба
WO2013105106A1 (en) 2011-11-03 2013-07-18 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
WO2013144977A2 (en) * 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
SK283261B6 (sk) 1996-07-18 2003-04-01 Merck Frosst Canada & Co. / Merck Frosst Canada & Cie. Substituované pyridíny, farmaceutický prostriedok s ich obsahom a ich použitie
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
EA002975B1 (ru) 1998-04-24 2002-12-26 Мерк Энд Ко., Инк. Способ синтеза ингибиторов циклооксигеназы-2
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
EP1248618B1 (en) 2006-03-22
ES2259295T3 (es) 2006-10-01
US6441002B1 (en) 2002-08-27
EP1248618A4 (en) 2003-05-14
WO2001037833A1 (en) 2001-05-31
JP4425514B2 (ja) 2010-03-03
PT1248618E (pt) 2006-07-31
CA2391650A1 (en) 2001-05-31
US20020198238A1 (en) 2002-12-26
US20030144327A1 (en) 2003-07-31
ATE320809T1 (de) 2006-04-15
AU776544B2 (en) 2004-09-16
CA2391650C (en) 2011-01-25
EP1248618A1 (en) 2002-10-16
DE60026877T2 (de) 2006-11-23
AU1803101A (en) 2001-06-04
DE60026877D1 (de) 2006-05-11
JP2003514859A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
DK1248618T3 (da) Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
NO990191D0 (no) Substituerte pyridiner som selektive syklooksygenase-2-inhibitorer
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
AU2001294009A1 (en) Methods of providing java tamperproofing
YU5503A (sh) Nesteroidni supresori zapaljenja
NO20072142L (no) Mellomprodukter for fremstilling av heterocyklylalkylpiperidinderivater og forbindelser for fremstilling av disse
WO2003029600A3 (en) Cementing system for wellbores
AU2002231628A1 (en) 4-6-diphenyl pyridine derivatives as antiinflammatory agents
WO2001030781A3 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
NO20011436L (no) 2,2,6,6-dietyl-dimetyl-1-alkoksy-piperidin-forbindelser og deres korresponderende 1-oksider
NO20032332D0 (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
AU2002356533A1 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
AU2001288092A1 (en) Method of crystallization
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
DZ3356A1 (en) Novel polymorph v of torasemide.
AU2001285388A1 (en) Open loop timing control for synchronous cdma systems
PT1073438E (pt) Composicoes orais de 8-cloro-6,11-dihidro-11-(4-piperidilidina)-5h-benzo¬5,6|ciclohepta¬1,2-b|piridina
AU2001294408A1 (en) Method for erecting a building, block and dowel therefore
NO20000290L (no) Isolasjonssystem, fremgangsmåte for isolering og anvendelse av isolasjonssystem
DE60118941D1 (de) Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
AU7766900A (en) Nicotinyl aspartyl ketones as inhibitors of caspase-3
DK1064265T3 (da) Syntese af 3-amino-2-chlor-4-methylenpyridin fra malononitril og acetone
AR053675A2 (es) Composicion herbicida
NO20024540D0 (no) Fremgangsmåte for overföring av stemmedatapakker